comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 22:23:42 - browse：42235

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Doctors' information doesn't help them choose wisely when sick

hotspot

WSS

EQRx, failed developer of low

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Gilead might be held responsible for not developing a drug

What we’ve learned from the Aduhelm mess

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Micronoma's microbiome cancer diagnostic approach under fire

leisure time

comprehensive

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

What should King Charles tell the public about his cancer?

Trump demands the U.S. pay no more for drugs than other countries … again

Amazon expands telehealth clinic nationwide

As demand for Covid shots wanes, Moderna seeks its next success

Robert F. Kennedy is pitching centrism on health, even on abortion

After affirmative action ruling, medical educators look to 'holistic review'

Sage hopes for a blockbuster in antidepressant now before FDA

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

5 important ways Henrietta Lacks changed medical science

entertainment

Biden report: The neurospychology of memory and aging

Senators start work on Medicare physician payment reform

The dental labor crisis is a moment of opportunity

The dental labor crisis is a moment of opportunity

A disappointing year of Humira biosimilars

Physician groups backed by private equity giant lobby on mergers

focus

hotspot

Wikipedia

focus